X0306 4 2020-09-18 0001634379 Metacrine, Inc. MTCR 0001329161 Adelman Robert J C/O METACRINE, INC. 3985 SORRENTO VALLEY BLVD., SUITE C SAN FRANCISCO CA 92121 true true Common Stock 2020-09-18 4 P 0 230000 13 A 230000 D Common Stock 2020-09-18 4 C 0 2829123 A 3059123 D Series A Convertible Preferred Stock 2020-09-18 4 C 0 1960784 0 D Common Stock 1960784 0 D Series B Convertible Preferred Stock 2020-09-18 4 C 0 472250 0 D Common Stock 472250 0 D Series C Convertible Preferred Stock 2020-09-18 4 C 0 396089 0 D Common Stock 396089 0 D Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date. The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein. Robert Adelman, by: /s/ David Pezeshki, as attorney-in-fact 2020-09-22